Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

H5N1 avian influenza in humans is a viral infection caused by avian influenza A(H5N1) viruses that primarily affect birds but can infect humans. According to the Centers for Disease Control and Prevention, 1,022 human cases have been reported globally since 1997, including 12 cases from August 2025 to June 2026. As per the H5N1 avian influenza in humans epidemiology forecast by Expert Market Research, ongoing surveillance remains important.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

H5N1 Avian Influenza in Humans – Number of Cases by Year

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

H5N1 Avian Influenza in Humans Epidemiology Forecast Report Coverage

Expert Market Research's “H5N1 Avian Influenza in Humans Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of H5N1 avian influenza in humans. It projects the future incidence and prevalence rates of H5N1 avian influenza in humans cases across various populations. The study covers age, gender, and type as major determinants of the H5N1 avian influenza in humans population. The report highlights patterns in the prevalence of H5N1 avian influenza in humans over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of H5N1 avian influenza in humans in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

H5N1 Avian Influenza in Humans Understanding: Disease Overview

H5N1 avian influenza is an infection caused by influenza A(H5N1) viruses that primarily circulate among birds but can infect mammals, including humans following close contact with infected animals or contaminated environments. Human infection can range from asymptomatic or mild illness to severe respiratory disease, pneumonia, acute respiratory distress syndrome, and death. H5N1 belongs to the broader group of avian influenza viruses, which includes multiple influenza A subtypes. Avian influenza viruses are also classified as low pathogenic or highly pathogenic based on their effects in poultry, rather than disease severity in humans.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Poultry workers, dairy workers, animal handlers, backyard poultry owners, and individuals with direct or close exposure to infected animals.

Key Diagnostic Method

Molecular testing, particularly RT-PCR, is central to laboratory confirmation of H5N1 infection.

Major Risk Factor

Direct or close contact with infected or sick animals, particularly poultry and other infected mammals, or contaminated environments.

Major gap in the market

Limited human case numbers and nonspecific early symptoms can create challenges in timely recognition, testing, and surveillance, particularly among exposed populations.

H5N1 Avian Influenza in Humans Epidemiology Perspective

The H5N1 avian influenza in humans epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the H5N1 avian influenza in humans epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for H5N1 avian influenza in humans and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to the Centers for Disease Control and Prevention (2026), 1,022 human H5N1 cases had been reported worldwide since 1997 as of June 10, 2026. The cases have occurred sporadically, primarily following direct or close exposure to infected poultry or other animals.

Gender-Specific Cases of the Disease

As per World Health Organization (2022), the two H5N1 cases identified in Spain in 2022 were both male poultry workers aged 19 and 27 years. Both infections were asymptomatic and associated with occupational exposure to infected poultry.

Age-Specific Cases of the Disease

According to the Centers for Disease Control and Prevention (2026), recent international H5N1 infections have occurred in both children and adults. Among eight Cambodian cases reported since August 2025, four occurred in children and four in adults.

Ethnicity-Wise Cases of the Disease

Human H5N1 infections have been reported across diverse geographic populations, with cases historically concentrated in countries where close contact with infected poultry or contaminated environments occurs.

Mortality and Survival Analysis of the Disease

According to the World Health Organization (2026), 993 human H5N1 cases and 477 deaths were reported globally from January 2003 through December 19, 2025, corresponding to a 48.0% case fatality rate.

H5N1 Avian Influenza in Humans – Number of Cases by Country

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise H5N1 Avian Influenza in Humans Epidemiology

The H5N1 Avian Influenza in Humans epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to the Centers for Disease Control and Prevention (2025), 70 human H5N1 cases were identified in the United States during 2024–2025 through mid-April 2025. Most confirmed cases were associated with exposure to infected animals, including poultry and dairy cattle.

Germany

Human H5N1 epidemiology in Germany has been characterized by the potential for zoonotic exposure where infected birds are present. Historical H5N1 activity in Germany involved extensive infection among wild birds, creating opportunities for exposure at the human-animal interface.

France

Human H5N1 infection risk in France is associated with occupational and environmental exposure to infected poultry. Such exposure can occur among poultry workers and individuals involved in handling or controlling infected birds.

Italy

Human H5N1 epidemiological risk in Italy is associated with exposure to infected birds and contaminated environments. Occupational activities involving poultry can increase opportunities for zoonotic exposure when H5N1 is circulating in birds.

Spain

According to the World Health Organization (2022), two human H5N1 infections were identified in Spain in 2022 among poultry workers. Both were 19- and 27-year-old males, were asymptomatic, and were associated with exposure to infected poultry or contaminated environments.

United Kingdom

According to the World Health Organization (2022), one human H5N1 infection was reported in the United Kingdom in 2021. The case was asymptomatic and occurred in an individual living with a large number of domestic birds infected with H5N1.

Japan

Human H5N1 epidemiological risk in Japan is associated with exposure to infected birds and contaminated environments. Historical H5N1 outbreaks in poultry have required surveillance and measures to reduce opportunities for human exposure.

India

According to the Centers for Disease Control and Prevention (2026), India reported one human H5N1 infection since August 2025. The case occurred in a child in March 2026, with backyard poultry in the village identified as a possible environmental exposure.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

A major unmet need across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India is the continued strengthening of early detection and surveillance among people with occupational or environmental exposure to infected animals. H5N1 infections can initially present with nonspecific respiratory or ocular symptoms, potentially complicating recognition. Opportunities therefore exist for expanded molecular testing capacity, integrated human-animal surveillance, rapid diagnostic approaches, and improved monitoring of high-risk occupational groups. India represents an important surveillance focus because additional human infections have been documented during 2025–2026, highlighting the need for sustained preparedness and rapid case identification.

H5N1 Avian Influenza in Humans: Treatment Overview

H5N1 avian influenza in humans treatment in humans primarily involves early administration of antiviral therapy and appropriate supportive care. Antiviral treatment with oseltamivir is recommended as soon as possible for patients with progressive, complicated, or severe disease and for individuals at increased risk of severe illness. Clinical management may include oxygen supplementation, respiratory support, fluid management, and treatment of complications according to disease severity. Patients should also undergo appropriate clinical assessment, laboratory testing, monitoring, and infection-control measures. Current seasonal influenza vaccines do not provide protection against human infection with H5N1 viruses.

Key Questions Answered

  • What is the current and projected burden of H5N1 avian influenza in humans across the 8 major markets?
  • Which countries across the 8 major markets account for the highest H5N1 avian influenza in humans patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of H5N1 avian influenza in humans across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of H5N1 avian influenza in humans across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of H5N1 avian influenza in humans across the 8 major markets?
  • How do major comorbidities and risk factors influence H5N1 avian influenza in humans epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of H5N1 avian influenza in humans across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the H5N1 avian influenza in humans landscape across the 8 major markets?
  • Which therapeutic areas linked to H5N1 avian influenza in humans are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the H5N1 avian influenza in humans epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on H5N1 avian influenza in humans epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for H5N1 avian influenza in humans across the 8 major markets?

Scope of the H5N1 Avian Influenza in Humans Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of H5N1 avian influenza in humans based on several factors.
  • H5N1 Avian Influenza in Humans Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The H5N1 avian influenza in humans report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Influenza Medication Market

Influenza A Infections Pipeline Analysis Report

Seasonal Influenza Epidemiology Forecast

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us